EverHint – EMA10 × EMA30 Crossover Signals for Jan 30, 2026 – Healthcare Leads with 14 Setups

What This Signal Is (Quick)

This strategy detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30):

• Buy Signal (EMA10_x_EMA30_Buy): EMA(10) crosses above EMA(30) on today's close

  • Short-term momentum overtakes medium-term trend
  • Suggests acceleration in upward price movement
  • Ideal for swing trading (1-4 week holding periods)

• Sell Signal (EMA10_x_EMA30_Sell): EMA(10) crosses below EMA(30) on today's close

  • Short-term momentum weakens below medium-term trend
  • Suggests deceleration or reversal of upward movement
  • Can signal exit points or short entry opportunities

Key Characteristics:

• Uses two EMAs (both exponential) for faster response to price changes
• More responsive than EMA10 x SMA50, generating more frequent signals
• Better suited for capturing short-to-medium term momentum shifts
• Higher sensitivity means more signals but also higher whipsaw risk in choppy markets

Key Criteria:

• Buy: EMA10 crosses above EMA30

• Sell: EMA10 crosses below EMA30

• Minimum ADV: $40M (liquidity filter)

• Earnings buffer: 7 days pre/post earnings

• Fresh crossover: Detected on today's close

Holding Period: 1-4 weeks
Risk Level: Medium

How We Ranked Today

Ranked by RSI (lower RSI for buy signals = more oversold)

📈 Buy-Side Signals (18 Total)

Ranked by RSI (lower RSI for buy signals = more oversold):

📉 Sell-Side Signals (Top 25 of 45 total)

Ranked by RSI (higher RSI for sell signals = more overbought):

Field Notes

Sector concentration: Healthcare (14), Consumer Cyclical (12), Industrials (11)

Insider selling: LC (LendingClub Corporation, $-242K), OKTA (Okta, Inc., $-1.3M), OMER (Omeros Corporation, $-751K)

Near-term earnings: DXC (DXC Technology Company), SKY (Champion Homes, Inc.) report within 7 days. Higher volatility risk.

Data coverage: 19.0% insider, 3.2% congressional (1 recent/90d, 1 older/1y), 93.7% earnings, 100.0% analyst, 38.1% news

Congressional Activity

T (AT&T Inc.) 🔴 Bearish (90d)

• 1 sale by 1 member
• Top seller: Hou. Harold Dallas Rogers (KY) - 1 transaction ($1,001 - $15,000)
• Top buyer: Hou. David Taylor (OH) - 1 transaction ($1,001 - $15,000)

VZ (Verizon Communications Inc.) 🟢 Bullish (1y)

• 1 purchase by 1 member
• Top buyer: Hou. Tim Moore (NC) - 1 transaction ($15,001 - $50,000)

Recent Headlines

ALAB (Astera Labs, Inc.)

• Federated Hermes Inc. Boosts Holdings in Astera Labs, Inc. $ALAB (source)
• Astera Labs, Inc. (ALAB) Sees a More Significant Dip Than Broader Market: Some Facts to Know (source)
• Estate Counselors LLC Buys New Position in Astera Labs, Inc. $ALAB (source)

AN (AutoNation, Inc.)

• AutoNation (AN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (source)
• 5 Broker-Loved Stocks to Watch Amid Steady Start to Q4 Earnings Season (source)
• Will AutoNation (AN) Beat Estimates Again in Its Next Earnings Report? (source)

ARGX (argenx SE)

• Artisan Global Opportunities Fund Q4 2025 Portfolio Update (source)
• Alta Wealth Advisors LLC Makes New $623,000 Investment in argenex SE $ARGX (source)
• HRMY or ARGX: Which Is the Better Value Stock Right Now? (source)

AS (Amer Sports, Inc.)

• Amer Sports Announces Redemption of $80 Million of 6.750% Senior Secured Notes Due 2031 and Announces Earnings Date (source)
• Why Amer Sports, Inc. (AS) is Poised to Beat Earnings Estimates Again (source)
• Amer Sports, Inc. (NYSE:AS) Given Consensus Recommendation of “Buy” by Brokerages (source)

BIIB (Biogen Inc.)

• Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (source)
• Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (source)
• Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options (source)
• FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review (source)

BN (Brookfield Corporation)

• Brookfield Renewable Partners L.P. Limited Partnership Units (BEP.UN:CA) Q4 2025 Earnings Call Transcript (source)
• Brookfield Infrastructure Is Now One Of The Most Important Dividend Growth Stocks (source)
• Brookfield Renewable Reports Strong 2025 Results and Announces 5% Distribution Increase (source)
• Brookfield Business Partners Reports 2025 Year End Results (source)
• This Isn't An AI Bubble - It's An $85 Trillion Infrastructure Boom (source)
• Brookfield Infrastructure Reports Solid 2025 Year-End Results & Declares 17th Consecutive Distribution Increase (source)
• Third Avenue Real Estate Value Fund Q4 2025 Portfolio Activity (source)
• Cooke & Bieler LP Trims Stock Holdings in Brookfield Corporation $BN (source)
• Beyond the Hype: 3 Unexpected AI Stocks Hiding in Plain Sight (source)
• Should You Buy Brookfield Asset Management While It's Below $55? (source)
• The AI Winner Nobody Is Talking About: Self-Storage REITs (source)
• My 6 Highest Conviction Stock Picks for 2026 and Beyond (source)

CADE (Cadence Bank)

• TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 (source)
• 5 Stocks Worth Watching on Their Fresh Dividend Hikes (source)

CB (Chubb Limited)

• Chubb Limited $CB Stake Decreased by Cullen Frost Bankers Inc. (source)
• 35% of Warren Buffett's $309 Billion Berkshire Hathaway Portfolio Is Invested in These 5 Financial Stocks. Here's the Best of the Bunch for 2026. (source)

DECK (Deckers Outdoor Corporation)

• Deckers Outdoor Corporation (NYSE:DECK) Receives Average Recommendation of “Hold” from Brokerages (source)

PSTG (Pure Storage, Inc.)

• Why Pure Storage (PSTG) Dipped More Than Broader Market Today (source)
• STX's HDDs vs. PSTG's Flash Bet: Which Storage Play is Better? (source)
• Pure Storage, Inc. $PSTG Shares Sold by Federated Hermes Inc. (source)
• Why Pure Storage (PSTG) Outpaced the Stock Market Today (source)

RHI (Robert Half Inc.)

• Here's Why This Cyclical Company's Stock Rocketed 26% Higher Today (source)
• Robert Half's (RHI) Q4 Earnings Surpass Estimates, Decline Y/Y (source)
• Robert Half International Q4 Earnings & Revenues Beat Estimates (source)
• Robert Half Q4 Earnings Call Highlights (source)
• Robert Half (RHI) Reports Q4 Earnings: What Key Metrics Have to Say (source)
• Robert Half (RHI) Surpasses Q4 Earnings and Revenue Estimates (source)
• Robert Half Reports Fourth-quarter Financial Results (source)
• Robert Half Announces Senior Leadership Promotions to Support Continued Innovation (source)

RYAAY (Ryanair Holdings plc)

• Wizz Air: JPMorgan stays bearish as Ryanair ramps up competition (source)
• Ryanair Earnings Came Ahead of Estimates in Q3, Revenues Up Y/Y (source)
• Ryanair expects to offer free Wi-Fi in 3-5 years as technology improves (source)
• Ryanair CEO Michael O'Leary Thinks Airlines Will Offer Free Onboard Wi-Fi To Customers After Feud With Elon Musk (source)

SANM (Sanmina Corporation)

• Here's Why Sanmina (SANM) is a Strong Growth Stock (source)
• Are Investors Undervaluing Sanmina (SANM) Right Now? (source)
• Why Sanmina (SANM) is a Top Value Stock for the Long-Term (source)
• Sanmina: Post-Earnings Crash Presents Undervalued AI Opportunity (source)
• Sanmina Q1 Earnings Call Highlights (source)
• Why Sanmina Stock Plummeted by Almost 22% Today (source)
• Sanmina Reports First Quarter Fiscal 2026 Financial Results (source)

SIGI (Selective Insurance Group, Inc.)

• Selective Insurance Group, Inc. (SIGI) Q4 2025 Earnings Call Transcript (source)
• Selective Insurance 4Q Earnings Beat Estimates on Solid Underwriting (source)
• Selective Insurance (SIGI) Reports Q4 Earnings: What Key Metrics Have to Say (source)
• Selective Insurance (SIGI) Beats Q4 Earnings and Revenue Estimates (source)
• Selective Reports Fourth Quarter and Year-End 2025 Results (source)
• What Analyst Projections for Key Metrics Reveal About Selective Insurance (SIGI) Q4 Earnings (source)

SRPT (Sarepta Therapeutics, Inc.)

• Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients (source)
• Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (source)

SYK (Stryker Corporation)

• SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption (source)
• Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript (source)
• Stryker Corp (SYK) Q4 2025 Earnings Call Highlights: Record Revenue and Robust Growth Amid Challenges (source)
• Compared to Estimates, Stryker (SYK) Q4 Earnings: A Look at Key Metrics (source)
• Stryker raises annual profit forecast on strong sales for medical devices (source)
• Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates (source)
• Stryker reports 2025 operating results and 2026 outlook (source)
• SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand (source)

T (AT&T Inc.)

• Stock Market Today, Jan. 28: AT&T Rises After Earnings Beat and New Buyback Plan (source)
• AT&T Inc (T) Q4 2025 Earnings Call Highlights: Strong Growth in Fiber and 5G Subscribers (source)
• Dow Jones Today: Stock Indexes Tick Higher After Fed Holds Interest Rates Steady; S&P 500 Hits 7000; Big Tech Earnings on Tap (source)
• AT&T Inc. (T) Q4 2025 Earnings Call Transcript (source)
• AT&T: Upcoming Acquisitions Reset The Dividend And Buyback Outlook (source)
• AT&T Beats Q4 Earnings Estimates on Solid Wireless & Fiber Demand (source)
• AT&T Stock Charges Higher on Upbeat Results, Forecast (source)
• Compared to Estimates, AT&T (T) Q4 Earnings: A Look at Key Metrics (source)
• AT&T reports stronger-than-expected fourth quarter results (source)
• AT&T Offsets Legacy Slump With Solid Wireless Growth (source)
• AT&T (T) Q4 Earnings and Revenues Beat Estimates (source)
• AT&T's earnings impress as subscriber growth booms and the stock soars (source)
• AT&T Sales Rise on Higher Wireless, Consumer Revenue (source)
• AT&T Reports Strong Fourth-Quarter and Full-Year 2025 Financial Performance Driven by Growth in Converged Fiber and 5G Customers (source)
• AT&T bets on fiber, spectrum deals to forecast annual profit above expectations (source)
• Market Today: Fed Hold Looms; UPS Cuts, Amazon Grocery Shift (source)
• AT&T Stock Is on a Bad Run. Why Earnings Can Send a Better Signal. (source)
• Wall Street Week Ahead (source)
• Commerzbank Aktiengesellschaft FI Purchases 48,240 Shares of AT&T Inc. $T (source)
• AT&T Q4 Earnings Preview: Absurd Combination Of 4.7% Yield And 4.4x P/Cash Ratio (source)
• AT&T: 3 Alternatives To The 6% Yielding Preferreds Before They Move To Junk (source)
• Countdown to AT&T (T) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (source)

Market Context

Major indices closed modestly lower, with the Nasdaq leading declines at -0.50%, followed by the Dow Jones at -0.20% and S&P 500 at -0.12%. This broad-based pullback signals a cautious risk appetite amid a slightly risk-off tone, potentially challenging short-term EMA10/EMA30 crossover strategies that thrive on sustained trends. In such conditions, signals may face headwinds from fading momentum, increasing the likelihood of false crossovers if broader market trends weaken further.

The VIX dropped sharply by -6.84% to 17.44, reflecting subdued volatility and reduced intraday swings. Lower volatility supports EMA-based signals by minimizing whipsaws, allowing 10-period EMAs to more reliably track emerging trends relative to the 30-period EMA. With 63 total signals generated, this environment favors cleaner entries, particularly for strategies capturing persistent moves rather than erratic noise.

Healthcare emerging as the top sector amid this setup points to sector rotation toward defensives, bolstered by the mild equity dip and calming VIX. EMA10/EMA30 signals in leading sectors like Healthcare could outperform in a low-volatility, risk-averse climate, as capital flows prioritize stability over high-beta areas, enhancing signal conviction where crossovers align with rotational strength.

⚠️ Extended Non-Trading Period Alert

Important: Saturday, January 31 through Sunday, February 01 were non-trading days (weekend).

What this means:

• Markets will not reopen until Monday, February 02
• News and events occurring over this extended non-trading period may significantly influence market sentiment
• Monitor news flow closely during this period
• Be prepared for potential gaps or increased volatility when markets reopen
• Earnings announcements, geopolitical events, or major news during this period can lead to significant price movements at the open
• Consider adjusting position sizes or using protective stops given the extended gap risk

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (14 signals) suggests sector-specific rotation. 12 signals showing insider selling warrant caution. Average RSI of 40 indicates oversold conditions.

Trading tips for this strategy:

• Entry timing: Enter on pullback after crossover or at crossover close price
• Position sizing: Start with 2-3% of portfolio per signal (swing trade size)
• Stop loss: Below recent swing low for buys, above recent swing high for sells
• Take profit: 5-10% target for swings, or trail stop at EMA10
• Time stop: Exit if crossover reverses within 1-2 weeks (failed signal)

Risk warning: EMA crossovers generate more signals but higher whipsaw risk in ranging markets. Use with trend filter (price vs SMA200)

Sharing Call-to-Action

🟢🟢 If this clarity helped your research, liking, sharing, or subscribing helps keep this project strong.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/